French Fill-Finish CDMO Guide (2026)

France imports most of its active ingredients but it does a serious amount of sterile fill-finish inside its borders. Fareva, Recipharm, Unither, Delpharm, Cenexi, and the new Adragos-owned Maisons-Alfort site run aseptic lines for vials, pre-filled syringes, cartridges, BFS unit-doses, and lyophilized product. The global sterile injectables CDMO market is sized at USD 4.73 billion in 2025 and forecast to reach USD 10.91 billion by 2034, and France is one of the few EU countries with the plants to win a real share of it.

Why France Matters in Fill-Finish Right Now

France runs 271 pharmaceutical production sites and employs close to 100,000 people, producing roughly 3.5 billion medicine boxes a year. The country is the second-largest European player in biomedicines after Germany. Most of that footprint sits in finished drug-product, not API. Tablets, ampoules, vials, BFS containers, pre-filled syringes, and lyophilized injectables all roll off French lines daily, often for European and US markets.

Two forces are pushing capital into French sterile fill-finish at the same time.

The first is France 2030, the national reindustrialization plan launched by the Élysée. According to PharmaBoardroom’s reporting on France 2030, the program commits EUR 7.5 billion to health innovation, including biomanufacturing and advanced therapies, with a target of producing 60 biomedicines domestically by 2030, up from 47 today. Inside that envelope, France 2030 has already backed 14 industrial projects with close to EUR 300 million to relocate or strengthen production of essential medicines, including injectables.

The second is the EU Critical Medicines Act. On 2 December 2025 the Council of the EU agreed its position on new rules designed to boost EU manufacturing of critical medicines and cut reliance on third countries. The European Medicines Agency welcomed the political agreement on the Critical Medicines Act and is now preparing implementation guidance. French fill-finish sites with Annex 1 compliance, EMA inspection history, and FDA dual qualification are first in line to absorb that work.

As Isabelle Van Rycke, President of UPSA, put it in French Healthcare’s industry brief, “Producing in France means guaranteeing the quality and availability of treatments for European patients.” That is now a procurement argument, not a slogan.

The Anchors of French Fill-Finish

Fareva (Pau, Val-de-Reuil, and Group Network)

Fareva is one of the largest privately held CDMOs in Europe and runs sterile injectable operations from its Pau site in southwestern France. On 16 June 2025 Fareva opened a new GMP sterile pilot unit in Pau dedicated to liquid and lyophilized injectables. The unit covers formulation and aseptic filling of monoclonal antibodies, mRNA in LNP form, proteins, peptides, recombinant proteins, and antibody-drug conjugates. Batch sizes run from 200 to 8,000 vials, the equipment complies with the revised Annex 1, and the line is designed to handle high-potency molecules up to OEB 5.

That is exactly the spec sheet biotech sponsors are looking for in 2026. Sponsors with mAb, mRNA, and ADC programs need a partner who can bridge from Phase 1 clinical material to small commercial batches without forcing them to switch sites mid-program.

Unither Pharmaceuticals (Coutances)

Unither Pharmaceuticals is the world leader in Blow-Fill-Seal (BFS) unit-dose manufacturing, with industrial capacity above 5 billion units per year across production sites on three continents. The Coutances site in La Manche is one of the five core manufacturing locations and a key anchor for European BFS supply. BFS is the format of choice for sterile single-dose liquids, vaccines, and ophthalmic products where preservative-free, plastic, low-cost containers beat glass vials on both cost and clinical handling.

For French and global biotech sponsors developing sterile unit-dose products, Unither’s Coutances output is one of the few BFS commercial routes that does not depend on capacity in Asia.

Delpharm (11 sites in France)

Delpharm is among the top five CDMOs globally and runs 11 sites in France, plus additional plants in Europe and North America. The latest expansion is at Saint-Rémy, where on 20 June 2025 Delpharm commissioned a new Annex 1-compliant sterile filling line. Total investment was EUR 37 million, of which EUR 10.4 million came from French government support under France 2030. The line adds 45 million annual units of 2ml vial capacity at up to 24,000 vials per hour.

Delpharm’s strategy is consistent: a wide network of mid-sized plants, deep in oral solids, sterile vials, ophthalmics, and inhalation, focused on European supply continuity for sponsors who do not want their dossier living inside one mega-site.

Adragos Pharma at Maisons-Alfort (former Sanofi)

The newest entrant in French fill-finish is Adragos Pharma. On 1 April 2026 Adragos closed the acquisition of Sanofi’s commercial-scale sterile fill-finish site at Maisons-Alfort, one of the largest manufacturing facilities for sterile injectables in Europe. The site fills pre-filled syringes, liquid vials, and lyophilized vials at industrial scale. Adragos founder and CEO Dr. Andreas Raabe called it “a landmark acquisition for Adragos and a defining step in our growth journey.”

Combined with Adragos’ existing French and Swiss filling operations (including Baccinex in Courroux), Maisons-Alfort positions Adragos as one of the top sterile injectable CDMOs in Europe. For sponsors locked out of overbooked queues at the largest players, this is a new commercial-scale option opening up in 2026.

Recipharm France and Cenexi

Recipharm operates sterile fill-finish inside its broader 18-site EU network under EQT ownership. In its February 2024 announcement, Recipharm completed divestment of seven sites, including Pessac in France, sharpening focus on three segments: oral solid dosage, advanced therapies, and sterile fill and finish. Cenexi, headquartered in Fontenay-sous-Bois, fills vials, ampoules, and lyophilized product across French and Belgian sites for European pharma sponsors.

The French sterile CDMO field is therefore one of the deepest in Europe and the queues at each player look different. That is good news for sponsors looking for a second source. It is harder news for the CDMOs themselves, because the buying decision moves on commercial reach long before it moves on capacity.

The Demand Wave Behind These Investments

Why is everyone putting capital into French sterile capacity at the same time? The numbers explain it.

Precedence Research sizes the global sterile injectables CDMO market at USD 4.73 billion in 2025, growing at 9.73% CAGR to USD 10.91 billion by 2034. The same report flags three drivers: the expanding biologics and biosimilars pipeline, accelerating outsourcing as sponsors prioritize cost and time-to-market, and aseptic technology adoption (isolators, robotics, closed systems).

On top of that base, two specific demand shocks are real:

• GLP-1 receptor agonists. Diabetes and obesity injectables have triggered an industry-wide scramble for sterile fill-finish capacity. Pre-filled syringe and pen cartridge lines that were already booked are now booked further out.
• Lyophilization. Freeze-drying capacity is one of the hardest scarcities in the system. Multiple analyses describe queues running 18 to 24 months at the major lyo-equipped CDMOs.

For a French CDMO with Annex 1 isolators, lyo trays, or BFS lines, this is the most favorable demand environment in a decade. The technical credibility is not the issue. The bottleneck is reaching the 300 to 600 biotech and pharma sponsors who decide where their drug product runs.

Why Conventional Sales Channels Are Failing French Fill-Finish CDMOs

French sterile CDMOs sell the way the industry sold in 2005: through trade fairs, scientific partnerships, government tender networks, and a small bench of senior BD reps. Each channel is showing diminishing returns.

CPHI Worldwide, Pharmapack, INTERPHEX, BIO International. CPHI Frankfurt 2025 drew 62,000 attendees from 166 countries, making it the largest CPHI Europe to date. A booth runs USD 15,000 to 50,000 before staffing, travel, content, and post-show follow-up. You meet whoever walks by, mostly procurement, occasionally CMC. Cost per qualified lead: USD 300 to 900+, scaling linearly.

Partnership tracks and scientific advisor networks. Sterile fill-finish has always run partly on personal trust between technical operators. The advisor route is high quality but slow. Each KOL covers one narrow modality, takes months to onboard, and cannot be scaled into 200 accounts in parallel.

Government tendering (CEPS and EU public procurement). France’s Comité économique des produits de santé (CEPS) and equivalent EU procurement bodies do drive volume, but the qualification cycles run 12 to 24 months and the contracts are concentrated among a handful of legacy suppliers. CEPS is not where a new sterile capability gets discovered. It is where decade-old relationships get renewed.

Broker and distributor networks. Brokers find their margin in opacity. They own the customer relationship, hide who the end sponsor is, and switch suppliers when a cheaper slot opens elsewhere. You lose accounts you never knew you had.

Field sales representatives. A pharma-experienced BD rep covering one European market costs USD 100,000 to 150,000 fully loaded. To cover Germany, France, Italy, the UK, the US, Japan, and Korea you need at least six. Most mid-sized French CDMOs cannot hire and retain that team. Cost per qualified lead: USD 500 to 1,200+.

Cold calling across borders. Reaching the buying committee at a single biopharma sponsor means touching procurement, CMC, quality, regulatory, and supply chain. That is 20+ targeted touches per account, in the buyer’s native language, with deep GMP credibility. Finding fluent French, German, Italian, Japanese, and English BD callers who also speak sterile manufacturing is nearly impossible at scale.

Print and trade journal advertising. Still bought out of habit, read by almost no one inside a sponsor’s CMC team.

The structural flaw is the same across every channel: they reach one person at a time in an industry where supplier selection involves five to eleven stakeholders per account, according to Gartner research on B2B buying groups.

What Multi-Threaded Outbound Looks Like for a French Sterile CDMO

A modern AI-powered outbound engine treats a target sponsor as a buying committee, not a contact. For a French fill-finish CDMO that means parallel, role-specific outreach across:

• CMC leads and drug-product directors receive technical content on fill formats, isolator technology, lyo cycles, BFS suitability, and Annex 1 readiness.
• Quality and regulatory affairs heads receive EMA inspection history, FDA track record, DMF/CEP support, and audit dossiers.
• Procurement and supply-chain managers receive capacity availability, lead-time data, and dual-source positioning against the largest CDMOs.
• Project managers and outsourcing leads receive case examples and onboarding timelines specific to vials, PFS, BFS, or lyophilized product.

Around those role-based messages, the engine layers signal detection. When a target sponsor publishes a Phase III readout, a new injectable filing, a facility delay, a procurement leadership change, or an investor commitment to expand a pipeline, your outreach lands the same week. When a competing CDMO publishes a capacity warning, your engine flags every sponsor likely to be affected.

This is where the cost curve flips. Trade fairs and field sales scale linearly: every new market needs another booth or another rep. AI outbound scales sub-linearly. The second 1,000 prospects cost less to reach than the first 1,000 because targeting, sequencing, and content libraries compound over time. Cost per qualified lead with AI outbound: USD 150 to 300, declining as the engine learns which messaging works for biologics versus vaccines versus ADCs versus BFS unit doses.

Where French Fill-Finish CDMOs Can Win Quickly

Three positioning angles are open right now to any French CDMO with sterile capacity.

1. Annex 1 readiness. EU GMP Annex 1 full enforcement landed in 2024 and sponsors are still rebuilding their supplier maps around it. French CDMOs with isolators, documented contamination control strategies, and Annex 1-compliant lines (Delpharm Saint-Rémy, Fareva Pau, Adragos Maisons-Alfort) have an immediate story.
2. EU sovereignty for North American sponsors. US biotechs facing capacity bottlenecks and tariff uncertainty want a European site with FDA inspection history. A French CDMO with EMA and FDA dual qualification is one of the strongest answers to that brief.
3. Modality-specific capability. BFS unit-dose (Unither), pre-filled syringes (Adragos Maisons-Alfort), lyophilized clinical product (Fareva Pau), and high-potency injectables (Fareva, Delpharm, Recipharm) each map to a distinct biotech sponsor segment. None of these audiences are reachable through a single channel.

Each angle is a wedge for a structured outbound program targeting a finite list of 300 to 600 global sponsors. The stack to run those programs at French-quality discretion already exists.

How to Approach This Without Disrupting Your Operations

French pharmaceutical companies have their own pace and their own norms. Fill-finish CDMOs do not want to bolt on a US-style outbound machine that risks brand damage or compliance exposure. The path forward should be quieter.

1. Define the ICP precisely. Vaccine sponsors, GLP-1 developers, ADC innovators, ophthalmics start-ups, and biologics scale-ups each buy fill-finish differently. Pick the lane.
2. Map 300 to 600 target sponsors and their committees. Five to eleven contacts each, validated, current titles, current programs.
3. Stage the technical content. Annex 1 dossiers, inspection track record, capacity windows, lyo cycle data, BFS qualification packs ready for digital delivery.
4. Run multi-threaded campaigns in the buyer’s language. French, English, German, Japanese where the sponsor sits.
5. Measure response by role, modality, and signal type. Iterate quarterly.

papaverAI runs this stack for B2B manufacturers. Our case studies show what the operational rhythm looks like once the engine is live. If you want to see whether the model fits a French sterile fill-finish CDMO setup, get in touch.

Related Reading

• French Pharma and Biotech: Export Guide (2026)
• Swiss Vaccine Fill-Finish CDMOs (2026)
• France Manufacturing Exports: Growth Guide (2026)

Frequently Asked Questions

How big is the French fill-finish CDMO field in 2026?

France runs 271 pharmaceutical production sites with close to 100,000 employees and is the second-largest European player in biomedicines. The global sterile injectables CDMO market is sized at USD 4.73 billion in 2025 and is forecast to reach USD 10.91 billion by 2034 at 9.73% CAGR. France’s fill-finish CDMOs sit inside the European share of that market, with Fareva, Unither, Delpharm, Adragos-owned Maisons-Alfort, Cenexi, and Recipharm anchoring the field.

Which French CDMOs handle sterile fill-finish at commercial scale?

Fareva runs sterile injectable operations from Pau, where it opened a new GMP sterile pilot unit for liquid and lyophilized biologics in June 2025. Unither leads global BFS unit-dose manufacturing from Coutances. Delpharm runs 11 sites across France, including the new Saint-Rémy Annex 1 line commissioned in June 2025. Adragos Pharma closed its acquisition of Sanofi’s Maisons-Alfort sterile site in April 2026. Cenexi and Recipharm round out the field.

Why is France investing so heavily in fill-finish capacity now?

France 2030 commits EUR 7.5 billion to health innovation including biomanufacturing, with a target of 60 domestic biomedicines by 2030. The Saint-Rémy line alone received EUR 10.4 million in French government support. On top of that, the EU Critical Medicines Act, which reached Council agreement on 2 December 2025, is designed to push more critical medicine production into Europe and reduce reliance on third countries.

How is AI-powered outbound different from CPHI and Pharmapack for fill-finish CDMOs?

Trade fairs reach whoever walks past your booth, mostly procurement, at USD 300 to 900+ per qualified lead, and they scale linearly. AI outbound maps the full buying committee at 300 to 600 sponsors, delivers role-specific technical content to CMC, quality, regulatory, and procurement, and detects signals like Phase III readouts or facility delays. Cost per qualified lead starts at USD 150 to 300 and decreases as the engine learns.

Can AI outbound handle the technical depth of sterile manufacturing sales?

Yes, when set up correctly. The engine carries your technical content but does not generate regulatory claims or modify your dossiers. CMC leads receive your fill formats and Annex 1 alignment. Quality heads receive your inspection history. Procurement receives your capacity and lead-time positioning. Your team owns every technical claim. The engine handles reach, sequencing, and timing.

---

If you run a French fill-finish CDMO and want a pipeline that does not depend on CPHI traffic, get in touch with papaverAI.